CL2013001324A1 - Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer. - Google Patents
Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.Info
- Publication number
- CL2013001324A1 CL2013001324A1 CL2013001324A CL2013001324A CL2013001324A1 CL 2013001324 A1 CL2013001324 A1 CL 2013001324A1 CL 2013001324 A CL2013001324 A CL 2013001324A CL 2013001324 A CL2013001324 A CL 2013001324A CL 2013001324 A1 CL2013001324 A1 CL 2013001324A1
- Authority
- CL
- Chile
- Prior art keywords
- kit
- chemotherapeutic agents
- treat cancer
- additional chemotherapeutic
- additional
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41327510P | 2010-11-12 | 2010-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013001324A1 true CL2013001324A1 (es) | 2014-05-16 |
Family
ID=46048353
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013001324A CL2013001324A1 (es) | 2010-11-12 | 2013-05-13 | Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer. |
CL2013001322A CL2013001322A1 (es) | 2010-11-12 | 2013-05-13 | Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013001322A CL2013001322A1 (es) | 2010-11-12 | 2013-05-13 | Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales. |
Country Status (16)
Country | Link |
---|---|
US (3) | US8987281B2 (es) |
EP (2) | EP2638395A4 (es) |
JP (2) | JP2013542263A (es) |
KR (2) | KR20130140033A (es) |
CN (2) | CN103403552B (es) |
AU (2) | AU2011325982C1 (es) |
BR (2) | BR112013011590A2 (es) |
CA (2) | CA2817219A1 (es) |
CL (2) | CL2013001324A1 (es) |
EA (2) | EA026168B1 (es) |
HK (1) | HK1189272A1 (es) |
IL (2) | IL226246A0 (es) |
MX (2) | MX2013005196A (es) |
SG (2) | SG190245A1 (es) |
WO (2) | WO2012065085A1 (es) |
ZA (2) | ZA201304226B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
JP5690589B2 (ja) | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 親水性スペーサーリンカーを含有する結合体 |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
BR112013011590A2 (pt) | 2010-11-12 | 2019-09-24 | Endocyte Inc | método de tratamento de câncer |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
WO2015077303A1 (en) | 2013-11-19 | 2015-05-28 | Purdue Research Foundation | Patient selection method for inflammation |
PT3134123T (pt) | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
CN103816548A (zh) * | 2014-03-11 | 2014-05-28 | 北京林业大学 | 靶向亲水性聚合物-雷公藤甲素结合物 |
KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
JP2017516760A (ja) * | 2014-04-14 | 2017-06-22 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 耐性がんを治療し、併用療法に用いるための薬物送達複合体 |
CN112638363A (zh) * | 2018-08-31 | 2021-04-09 | 太阳医药工业有限公司 | 卡铂的肠胃外剂型 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
EP2060272A3 (en) * | 2002-05-15 | 2009-05-27 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
DK1592457T3 (da) * | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
JP2008537778A (ja) * | 2005-03-30 | 2008-09-25 | パーデュー・リサーチ・ファウンデーション | 細胞の葉酸ビタミン受容体の定量化による癌予後診断法 |
US20080280937A1 (en) * | 2005-08-19 | 2008-11-13 | Christopher Paul Leamon | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives |
US20070065449A1 (en) * | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
JP5690589B2 (ja) | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 親水性スペーサーリンカーを含有する結合体 |
EP2349274A4 (en) * | 2008-09-17 | 2014-12-17 | Endocyte Inc | CONJUGATES OF ANTIFOLATES BINDING THE FOLATE RECEPTOR |
WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
JP2013501224A (ja) | 2009-07-31 | 2013-01-10 | エンドサイト,インク. | 葉酸を標的とした診断及び処置 |
BR112013011590A2 (pt) | 2010-11-12 | 2019-09-24 | Endocyte Inc | método de tratamento de câncer |
-
2011
- 2011-11-11 BR BR112013011590A patent/BR112013011590A2/pt not_active IP Right Cessation
- 2011-11-11 US US13/294,624 patent/US8987281B2/en not_active Expired - Fee Related
- 2011-11-11 KR KR1020137013272A patent/KR20130140033A/ko not_active Application Discontinuation
- 2011-11-11 CN CN201180061415.4A patent/CN103403552B/zh not_active Expired - Fee Related
- 2011-11-11 WO PCT/US2011/060407 patent/WO2012065085A1/en active Application Filing
- 2011-11-11 CA CA2817219A patent/CA2817219A1/en not_active Abandoned
- 2011-11-11 EP EP11839397.4A patent/EP2638395A4/en not_active Withdrawn
- 2011-11-11 SG SG2013036306A patent/SG190245A1/en unknown
- 2011-11-11 SG SG2013036280A patent/SG190244A1/en unknown
- 2011-11-11 AU AU2011325982A patent/AU2011325982C1/en not_active Ceased
- 2011-11-11 EP EP11840607.3A patent/EP2638397A4/en not_active Withdrawn
- 2011-11-11 MX MX2013005196A patent/MX2013005196A/es unknown
- 2011-11-11 EA EA201390695A patent/EA026168B1/ru not_active IP Right Cessation
- 2011-11-11 WO PCT/US2011/060395 patent/WO2012065079A1/en active Application Filing
- 2011-11-11 JP JP2013538937A patent/JP2013542263A/ja active Pending
- 2011-11-11 AU AU2011325989A patent/AU2011325989C1/en not_active Ceased
- 2011-11-11 KR KR1020137013270A patent/KR20130140032A/ko not_active Application Discontinuation
- 2011-11-11 CN CN2011800634321A patent/CN103282777A/zh active Pending
- 2011-11-11 BR BR112013011659A patent/BR112013011659A2/pt not_active IP Right Cessation
- 2011-11-11 EA EA201390694A patent/EA025069B1/ru not_active IP Right Cessation
- 2011-11-11 MX MX2013005194A patent/MX2013005194A/es unknown
- 2011-11-11 JP JP2013538939A patent/JP2013542264A/ja active Pending
- 2011-11-11 CA CA2817223A patent/CA2817223A1/en not_active Abandoned
- 2011-11-11 US US13/884,842 patent/US8883737B2/en not_active Expired - Fee Related
-
2013
- 2013-03-13 US US13/800,254 patent/US20140066383A1/en not_active Abandoned
- 2013-05-09 IL IL226246A patent/IL226246A0/en unknown
- 2013-05-09 IL IL226247A patent/IL226247A0/en unknown
- 2013-05-13 CL CL2013001324A patent/CL2013001324A1/es unknown
- 2013-05-13 CL CL2013001322A patent/CL2013001322A1/es unknown
- 2013-06-10 ZA ZA2013/04226A patent/ZA201304226B/en unknown
- 2013-06-10 ZA ZA2013/04225A patent/ZA201304225B/en unknown
-
2014
- 2014-03-10 HK HK14102373.7A patent/HK1189272A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013001324A1 (es) | Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer. | |
BR112013010988A2 (pt) | composição fluída e uso | |
SMT201400146B (it) | Morfolino pirimidine e loro uso in terapia | |
BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
BR112012003792A2 (pt) | gel tópico, e, uso do gel tópico. | |
CL2012003643A1 (es) | Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. | |
IT1400425B1 (it) | Modified snrnas for use in therapy. | |
BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
BRPI0914536A2 (pt) | tiadiazoliloxifenilamidinas e o uso destas como fungicidas | |
BR112012002349A2 (pt) | composto,e, uso do mesmo | |
BR112012004281A2 (pt) | uso de metformina tratamento e prevenção de câncer | |
BR112013010171A2 (pt) | combinação que consiste em um cartucho duplo e um misturador para uso do mesmo | |
CO6821883A2 (es) | Nuevos moduladores y métodos para su uso | |
BRPI1007494A2 (pt) | composto e uso do mesmo | |
DK3065759T3 (da) | Immunosuppressive midler og deres anvendelse i terapi | |
BR112013010272A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
BR112013001423A2 (pt) | método, método in vitro, uso e kit útil para realizar o método | |
BR112013015378A2 (pt) | misturador dinâmico e seu uso | |
BR112014010739A2 (pt) | agentes terapêuticos e uso dos mesmos | |
BR112012030927A2 (pt) | fosfaplatinas e seu uso para o tratamento de cânceres | |
CO6781486A2 (es) | Compuestos y su uso | |
BRPI0919794A2 (pt) | dispositivo para uso intracorpóreo, e, composto | |
BR112014009476A2 (pt) | refletor, iluminador e uso do iluminador | |
DK2883954T3 (da) | Peptidbibliotek og anvendelse deraf | |
CR20140362A (es) | Fenilimidazopirazoles sustituidos y su uso |